Latest news with #DengueTetravalent
The Print
01-08-2025
- Health
- The Print
70 pc enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre
'The trial involves over 10,000 participants, out of which more than 70 per cent enrolment has been completed. The trial has been implemented in 20 sites across India,' he said. The Indian Council of Medical Research (ICMR) has undertaken a clinical trial titled phase III, multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy, immunogenicity and safety of the single-dose Dengue Tetravalent vaccine, live attenuated (Recombinant, Lyophilised) – 'DengiAll', Jadhav said in a written reply. New Delhi, Aug 1 (PTI) Seventy per cent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll, has been completed, Minister of State for Health, Prataprao Jadhav, told Lok Sabha on Friday. The sites are JSS Medical College and Hospital, Mysuru (Karnataka), Bangalore Medical College and Research Institute, and All India Institute of Medical Sciences, Bibinagar (Telangana). The approximate budget for the trial is Rs 1.3 to 1.5 crore per site, Jadhav said. According to ICMR, there is no specific antiviral treatment or licensed vaccines for dengue and the treatment is supportive in nature, Jadhav said. A total of 5,73,563 laboratory confirmed dengue cases were reported through the Integrated Health Information Platform (IHIP) in 2024, according to information shared by the National Centre for Disease Control (NCDC) , . According to ICMR, all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV -4) are known to circulate and co-circulate in India. Multiple serotypes can be present in the same geographical region and can even infect the same individual at the same time. Hence, participants have been enrolled in the ICMR vaccine trial from different zones where these four serotypes circulate in order to test the efficacy of the vaccine against all four serotypes, Jadhav said. The minister also said that the Union Health Ministry, Director General of Health Services, and National Centre for Vector Borne Disease Control (NCVBDC) regularly monitor the situation of dengue outbreaks across the country for assessing the disease situation, preparedness, technical guidance and to sensitise and forewarn the states. Under the National Health Mission, adequate budgetary support is provided to states and Union territories for dengue control activities such as epidemic preparedness, monitoring, case management, vector control (provision of domestic breeding checkers, ASHA involvement, insecticide, fogging machines), training, intersectoral convergence, awareness activities, etc. For surveillance and free of cost diagnosis of dengue, Sentinel Surveillance Hospitals with laboratory facility and Apex Referral laboratories with advance diagnostic facilities have been identified across the country, Jadhav said. The government of India has developed national guidelines on dengue treatment/management, in consultation with experts, which have been shared with all the states and UTs for implementation. The guidelines emphasise the preparedness of hospitals for case treatment/management. In addition, advisories have been issued from time to time to states/UTs for prevention and control of dengue, including case management, the minister said. PTI PLB ARI This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Time of India
01-08-2025
- Health
- Time of India
70% enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre
Seventy percent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine , DengiAll , has been completed, Minister of State for Health, Prataprao Jadhav, told Lok Sabha on Friday. The Indian Council of Medical Research ( ICMR ) has undertaken a clinical trial titled phase III, multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy, immunogenicity and safety of the single-dose Dengue Tetravalent vaccine, live attenuated (Recombinant, Lyophilised) - 'DengiAll', Jadhav said in a written reply. Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity Project Management MCA Finance MBA PGDM Technology Healthcare Data Science Data Analytics CXO Design Thinking Data Science Leadership others healthcare Degree Others Digital Marketing Management Artificial Intelligence Product Management Public Policy Operations Management Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details "The trial involves over 10,000 participants, out of which more than 70 per cent enrolment has been completed. The trial has been implemented in 20 sites across India," he said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like War Thunder - Register now for free and play against over 75 Million real Players War Thunder Play Now Undo The sites are JSS Medical College and Hospital, Mysuru (Karnataka), Bangalore Medical College and Research Institute, and All India Institute of Medical Sciences, Bibinagar (Telangana). The approximate budget for the trial is Rs 1.3 to 1.5 crore per site, Jadhav said. Live Events According to ICMR, there is no specific antiviral treatment or licensed vaccines for dengue and the treatment is supportive in nature, Jadhav said. A total of 5,73,563 laboratory confirmed dengue cases were reported through the Integrated Health Information Platform (IHIP) in 2024, according to information shared by the National Centre for Disease Control (NCDC) , . According to ICMR, all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV -4) are known to circulate and co-circulate in India. Multiple serotypes can be present in the same geographical region and can even infect the same individual at the same time. Hence, participants have been enrolled in the ICMR vaccine trial from different zones where these four serotypes circulate in order to test the efficacy of the vaccine against all four serotypes, Jadhav said. The minister also said that the Union Health Ministry, Director General of Health Services, and National Centre for Vector Borne Disease Control (NCVBDC) regularly monitor the situation of dengue outbreaks across the country for assessing the disease situation, preparedness, technical guidance and to sensitise and forewarn the states. Under the National Health Mission, adequate budgetary support is provided to states and Union territories for dengue control activities such as epidemic preparedness, monitoring, case management, vector control (provision of domestic breeding checkers, ASHA involvement, insecticide, fogging machines), training, intersectoral convergence, awareness activities, etc. For surveillance and free of cost diagnosis of dengue, Sentinel Surveillance Hospitals with laboratory facility and Apex Referral laboratories with advance diagnostic facilities have been identified across the country, Jadhav said. The government of India has developed national guidelines on dengue treatment/management, in consultation with experts, which have been shared with all the states and UTs for implementation. The guidelines emphasise the preparedness of hospitals for case treatment/management. In addition, advisories have been issued from time to time to states/UTs for prevention and control of dengue, including case management, the minister said.
